美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

美国 · SEC FORM 4

Tyra Biosciences, Inc.

TYRA · Nasdaq · CIK 0001863127 · Healthcare · Biotechnology

内部人信号

45.0 / 100

1 位买方 · 1 条买入交易行 · $20.0K 买入总额

为什么有这个信号？

买方广度较低

买入规模较低

角色较强

近期性中等

确信度较强

评分构成

每条进度条表示其对当前分数的贡献；权重和公式保持不变。

Cluster+7.0 / 35

买入规模+2.8 / 25

角色+20.0 / 20

近期性+5.2 / 10

确信度+10.0 / 10

哪些因素限制了当前分数？

⚠ Cluster breadth is moderate · 1 insider(s), not 4+
⚠ Purchase size is modest relative to the model scale
✓ 角色得分高 · 买入者中职位最高的是：Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct

Fuhrman AlanChief Financial Officer

○○

Harris ToddPresident and CEO

○○

Rueb YuliyaVice President, Finance (PAO)

○○

Warner Douglas JChief Medical Officer

○

Ashar BhaveshChief Operating Officer

○

Verjee RehanDirector

●

● 买入▼ 卖出○ 其他

—

买方广度与集中度

合资格买方1

买入集中度100%最大买方： Verjee Rehan · $20.0K

聚集买入 · 15天1 insider峰值活动： 2026-09-09–2026-09-09

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

45.0 / 100

近期 Form 4 活动

1买入

14卖出

13其他 Form 4 交易行

19SEC 申报 · 365天

买入1 qualifying P line(s) · 180 days

卖出0 sale line(s) · 仅供背景

其他8 exercise / withholding / award / gift / other lines

10b5-1／计划交易Not assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M: -15.3%
3M: -39.0%
6M: -43.4%
12M: +46.3%

波动率与流动性

波动率: 66.9%
Beta: —
平均每日成交额: USD 17.1M

估值

市值: USD 1.2B
P/E: —

基本面

利润率: —
ROE: -46.3%
细分行业: Biotechnology

市场数据

价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-07-31 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数: 9,414,018
上期报告: 9,876,964
日均成交量: 1,066,287
回补天数: 8.8

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction date	Reporting owner	类型	证券	股数	平均价格	估算金额	来源
2026-09-09	Verjee Rehan	买入 (P)	Common Stock	972	USD 20.58	USD 20,001	SEC 申报 ↗
2025-06-16	Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.	买入 (P)	Common Stock	11,813	USD 10.13	USD 119,666	SEC 申报 ↗
2025-06-13	Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.	买入 (P)	Common Stock	120,167	USD 10.20	USD 1,225,703	SEC 申报 ↗
2025-06-12	Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.	买入 (P)	Common Stock	31,307	USD 10.20	USD 319,331	SEC 申报 ↗
2025-06-09	Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.	买入 (P)	Common Stock	186,850	USD 10.19	USD 1,904,002	SEC 申报 ↗
2025-06-05	Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.	买入 (P)	Common Stock	213,334	USD 10.04	USD 2,141,873	SEC 申报 ↗
2025-06-04	Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.	买入 (P)	Common Stock	997,864	USD 9.63	USD 9,609,430	SEC 申报 ↗
2024-11-08	Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.	买入 (P)	Common Stock	1,220,681	USD 16.25	USD 19,836,066	SEC 申报 ↗
2024-10-30	Fuhrman Alan	买入 (P)	Common Stock	9,500	USD 16.00	USD 152,000	SEC 申报 ↗
2021-12-17	Boxer Asset Management Inc.; Boxer Capital, LLC; LEWIS JOSEPH	买入 (P)	Common Stock	125,000	USD 13.12	USD 1,640,000	SEC 申报 ↗
2021-09-17	Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund III LP	买入 (P)	Common Stock	312,500	USD 16.00	USD 5,000,000	SEC 申报 ↗
2021-09-17	MORE ROBERT J	买入 (P)	Common Stock	156,250	USD 16.00	USD 2,500,000	SEC 申报 ↗
2021-09-17	Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.	买入 (P)	Common Stock	1,250,000	USD 16.00	USD 20,000,000	SEC 申报 ↗
2021-09-17	Boxer Asset Management Inc.; Boxer Capital, LLC; Davis Aaron I.; LEWIS JOSEPH; MVA Investors, LLC	买入 (P)	Common Stock	625,000	USD 16.00	USD 10,000,000	SEC 申报 ↗
2021-09-17	Alta Partners NextGen Fund II Management, LLC; Alta Partners NextGen Fund II, L.P.; Hudson Peter A; JANNEY DANIEL	买入 (P)	Common Stock	156,250	USD 16.00	USD 2,500,000	SEC 申报 ↗

Form 4 申报证据

28 transaction lines in the latest 365-day window; 248 in local history.

日期	申报人	类型	证券	股数	平均价格	估算金额	来源
2026-09-15	Rueb Yuliya	奖励／授予 (A)	Common Stock	2,925	USD 9.13	USD 26,705	SEC 申报 ↗
2026-09-15	Harris Todd	奖励／授予 (A)	Common Stock	864	USD 9.13	USD 7,888	SEC 申报 ↗
2026-09-15	Fuhrman Alan	奖励／授予 (A)	Common Stock	951	USD 9.13	USD 8,683	SEC 申报 ↗

展开近期 Form 4 证据 (25 grouped rows)

日期	申报人	类型	证券	股数	平均价格	估算金额	来源
2026-09-15	Rueb Yuliya	奖励／授予 (A)	Common Stock	2,925	USD 9.13	USD 26,705	SEC 申报 ↗
2026-09-15	Harris Todd	奖励／授予 (A)	Common Stock	864	USD 9.13	USD 7,888	SEC 申报 ↗
2026-09-15	Fuhrman Alan	奖励／授予 (A)	Common Stock	951	USD 9.13	USD 8,683	SEC 申报 ↗
2026-09-09	Verjee Rehan	买入 (P)	Common Stock	972	USD 20.58	USD 20,001	SEC 申报 ↗
2026-05-05	Warner Douglas J	奖励／授予 (A)	Common Stock	25,000	USD 0.00	USD 0	SEC 申报 ↗
2026-05-05	Rueb Yuliya	奖励／授予 (A)	Common Stock	8,333	USD 0.00	USD 0	SEC 申报 ↗
2026-05-05	Harris Todd	奖励／授予 (A)	Common Stock	79,000	USD 0.00	USD 0	SEC 申报 ↗
2026-05-05	Fuhrman Alan	奖励／授予 (A)	Common Stock	20,000	USD 0.00	USD 0	SEC 申报 ↗
2026-05-05	Ashar Bhavesh	奖励／授予 (A)	Common Stock	15,013	USD 0.00	USD 0	SEC 申报 ↗
2026-03-26	KAPLAN GILLA	期权行权／转换 (M)	Common Stock	53,172	USD 2.25	USD 119,637	SEC 申报 ↗
2026-03-26	KAPLAN GILLA	D (D)	Common Stock	53,172	USD 37.75	USD 2,007,243	SEC 申报 ↗
2026-03-25	KAPLAN GILLA	卖出 (S)	Common Stock	14,295	USD 36.97	USD 528,486	SEC 申报 ↗
2026-03-25	KAPLAN GILLA	期权行权／转换 (M)	Common Stock	14,295	USD 2.25	USD 32,164	SEC 申报 ↗
2026-03-13	Harris Todd	奖励／授予 (A)	Common Stock	1,463	USD 9.13	USD 13,357	SEC 申报 ↗
2026-03-13	Fuhrman Alan	奖励／授予 (A)	Common Stock	1,376	USD 9.13	USD 12,563	SEC 申报 ↗
2026-02-12	Bensen Daniel	卖出 (S)	Common Stock	8,000	USD 32.87	USD 262,981	SEC 申报 ↗
2026-01-12	Bensen Daniel	卖出 (S)	Common Stock	8,000	USD 28.52	USD 228,171	SEC 申报 ↗
2025-12-19	MORE ROBERT J	卖出 (S)	Common Stock	10,000	USD 25.00	USD 250,000	SEC 申报 ↗
2025-12-12	Bensen Daniel	卖出 (S)	Common Stock	8,000	USD 22.64	USD 181,120	SEC 申报 ↗
2025-11-21	MORE ROBERT J	卖出 (S)	Common Stock	246,871	USD 20.25	USD 4,999,138	SEC 申报 ↗
2025-11-19	Bensen Daniel	卖出 (S)	Common Stock	49,956	USD 16.32	USD 815,282	SEC 申报 ↗
2025-11-18	Bensen Daniel	卖出 (S)	Common Stock	75,633	USD 16.07	USD 1,215,422	SEC 申报 ↗
2025-11-17	Bensen Daniel	卖出 (S)	Common Stock	20,072	USD 16.18	USD 324,800	SEC 申报 ↗
2025-11-14	Bensen Daniel	卖出 (S)	Common Stock	110,228	USD 16.02	USD 1,765,853	SEC 申报 ↗
2025-11-13	Bensen Daniel	卖出 (S)	Common Stock	1,111	USD 16.00	USD 17,776	SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期	2026-10-18
排名版本	US-v1.2
数据质量	PASS ELIGIBLE · —
股票代码	TYRA
CIK	0001863127
行业	Healthcare
细分行业	Biotechnology Yahoo Finance
SEC SIC	2834 Pharmaceutical Preparations
交易所	Nasdaq

数据覆盖

本地 Form 4 历史	248 transaction lines from 2021-09-17 to 2026-09-15 15 P purchase lines · 134 S sale lines · 99 other lines
SEC 公司申报	打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.